Abstract
Corrigendum to ‘Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation’ by Mladen Solarić, Anders Bjartell, Ursula Thyroff-Friesinger and Davide Meani, Therapeutic Advances in Urology 2017, 9(6): 127–136. DOI: 10.1177/1756287217701665.
In June 2017 issue of Therapeutic Advances in Urology, in the above mentioned article, the x-axis values in Figure 4(c) are not correct. These values should be as follows: 0, 6, 12, 18 and 24 weeks. The correct figure is given below:
